Tumor imaging and therapy with labeled
monoclonal antibodies may be performed following injection of
radiolabeled antibodies specific to tumor antigens
Forms an insoluble antigen-antibody
complex that is precipitated at tumor site.
Radiopharmaceuticals: In-111
Prostascint for imaging prostate carcinoma, Y-90 Zevalin or I-131
Bexxar for Radioimmunotherapy of non-Hodgkin's lymphoma
Some liver uptake always observed;
small percent localizes in tumor; excretion is typically through kidneys
or GI tract
Imaging typically
begun several hours post injection; may continue out to 5 days with
In-111 or I-131 compounds
